Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Plasma Methylglyoxal Levels & Diabetic CVD

Diabetes Care; ePub 2018 May 21; Hanssen, et al

Plasma methylglyoxal (MGO) and glyoxal (GO) levels are associated with cardiovascular disease (CVD) mortality in individuals with type 2 diabetes, a recent study found. The study included 1,003 participants (mean age 59.1 years, 69.3% male, 61.6% with prior CVD) with type 2 diabetes. Researchers measured plasma MGO levels and 2 other dicarbonyls (GO and 3-deoxyglucosone) as baseline with mass spectrometry. Mean follow-up of CVD events was 8.6 years. Among the findings:

  • 287 individuals suffered from at least 1 CVD event; 346 died, and 60 underwent an amputation.
  • Higher MGO levels were associated with total and fatal CVD and with all-cause mortality, myocardial infarction, and amputations.
  • MGO levels were not associated with stroke.
  • Higher GO levels were significantly associated with fatal CVD, but not with other outcomes.

Citation:

Hanssen NMJ, Westerink J, Scheijen JJM, et al. Higher plasma methylglyoxal levels are associated with incident cardiovascular disease and mortality in individuals with type 2 diabetes. [Published online ahead of print May 21, 2018]. Diabetes Care. doi:10.2337/dc18-0159.